BTG acquires novel opioid agonist for post-operative pain control from CLL Pharma
The compound, to be called BTG6001, is an orally active opioid agonist with a long duration of action, potentially reducing the amount of analgesic required for effective pain control. Owing to its unique receptor profile, BTG6001 is also expected to show a superior side effect profile compared with current opiate analgesics. BTG plans to complete preclinical development and initiate Phase I clinical studies during 2008.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.